Millenium Biologix Signs Exclusive License Agreement to Enhance ACTES(TM)-C
This licensing agreement will allow Millenium to develop and use a specific combination of growth factors in its Autologous Clinical Tissue Engineering Systems for cartilage repair (ACTES(TM)-C), a point-of-care regeneration product for production of cartilage from the patient's own cell sample. This license agreement is expected to enhance the productivity of Millenium's ACTES-C. Through the development and use of this technology, Millenium will be able to significantly enhance the utility of the ACTES(TM) technology platform, and so address broader clinical indications.
Millenium anticipates the use of this technology in early ACTES commercial products. The agreement provides MIT with an upfront payment, followed by a royalty on sales of ACTES components that utilize the technology as part of the biological processing undertaken in the overall ACTES system.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.